About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Active Not RecruitingPhase 2

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Nivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Response To Idecabtagene Vicleucel

NCT06523621•Wake Forest University Health Sciences

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Multiple Myeloma

Interventions

Nivolumab

Locations

1

United States

Locations (1)

Levine Cancer Institute

Charlotte, North Carolina, United States

Key Dates

Start Date

February 28, 2025

Primary Completion Date

March 21, 2026

Completion Date

December 1, 2028

Last Updated

April 16, 2026

Related Studies

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528

Non-hodgkin LymphomaMultiple Myeloma

RECRUITINGPhase 1

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

NCT06215118

Multiple Myeloma

RECRUITINGPhase 3

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101

Multiple MyelomaNewly Diagnosed Multiple Myeloma

RECRUITINGPhase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05969860

Advanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+42 more

RECRUITINGPhase 4

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT06057402

Multiple Myeloma

Pre-malignant States to Hematologic Malignancies in Firefighters

NCT06870760

Clonal Hematopoiesis of Indeterminate PotentialMonoclonal Gammopathy+4 more

View all related studies

Sponsors

Lead Sponsor

Wake Forest University Health Sciences

Collaborators

Atrium Health Levine Cancer Institute
Bristol-Myers Squibb

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 16, 2026Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions